リバーセル株式会社

Rebirthel is a biotech company, focused on the Development and operationalization of cell-based cancer immunotherapies.

Operating in medtech based in Tokyo, Japan, リバーセル株式会社 was founded in 2019.

Profile

"Rebirthel is a pioneering biotech company focused on the development and operationalization of cell-based cancer immunotherapies. Utilizing cutting-edge technology developed by Dr. Hiroshi Kawamoto, Director of the Institute for Frontier Medical Sciences at Kyoto University, Rebirthel aims to provide innovative treatments for immune-related diseases such as cancer and infections. The company specializes in producing killer T cells derived from pluripotent stem cells, offering a novel approach to immunotherapy. By focusing on the production of allogeneic T cells that can be administered to anyone, Rebirthel is revolutionizing the field of immunotherapy. With a vision to pioneer the era of treating diseases with T cell products, Rebirthel is at the forefront of the immunotherapy industry. Leveraging patented technology, the company is dedicated to providing advanced treatments using killer T cells regenerated from pluripotent stem cells, striving to offer cutting-edge therapies for patients in need."

As a business in medtech, リバーセル株式会社 is listed here with the public details available about it.

Tokyo, Japan is where the company is located.

It is recorded at the Plug and Play portfolio startup stage.

The company reports a headcount in the 1-10 range.

Website: rebirthel.com